Sign In
Buy OKYO
$1.55
+0.0700 (+4.73%)
At Close: Jul 24, 2026
OKYO Pharma secures FDA fast-track designation for urcosimod for neuropathic corneal pain
08:36am, Thursday, 01'st May 2025
OKYO Pharma Ltd (NASDAQ:OKYO) announced that the US Food and Drug Administration has granted Fast Track designation to urcosimod for the treatment of neuropathic corneal pain (NCP), a chronic ocular
OKYO Pharma accelerates clinical development of urcosimod for neuropathic corneal pain
10:02am, Wednesday, 30'th Apr 2025
OKYO Pharma Ltd (NASDAQ:OKYO) has announced plans to accelerate the clinical development of urcosimod, formerly called OK-101, to treat neuropathic corneal pain. The company has chosen to end its Phas
OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
07:00am, Wednesday, 30'th Apr 2025
LONDON and NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) t
OKYO Pharma CEO discusses FDA Fast Track filing for urcosimod - ICYMI
09:08am, Saturday, 05'th Apr 2025
OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob talked with Proactive about the company's recent developments, including the formal naming of its drug candidate OK-101 as urcosimod. Jacob discussed the c
OKYO Pharma reports long-term shelf stability of corneal pain treatment
08:49am, Monday, 31'st Mar 2025
OKYO Pharma Ltd (NASDAQ:OKYO) said on Monday that its experimental drug urcosimod has demonstrated stability for over two and a half years in single-use ampoules. The biopharmaceutical company's confi
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod
08:00am, Monday, 31'st Mar 2025
LONDON and NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic
OKYO Pharma seeks FDA Fast Track designation for neuropathic corneal pain treatment
09:09am, Monday, 10'th Mar 2025
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has filed a Fast Track designation application with the US Food and Drug Administration (FDA) for urcosimod, for the treatment of neuropathic corneal pa
OKYO Pharma secures USAN designation ‘urcosimod' for lead asset
09:10am, Wednesday, 12'th Feb 2025
OKYO Pharma Ltd (NASDAQ:OKYO) announced that its lead asset, OK-101, has been granted the United States Adopted Name (USAN) "urcosimod." The company said the designation reinforces its progress in dev
OKYO Pharma poised for multi-billion-dollar opportunity in ocular treatment market, analysts believe
12:46pm, Friday, 31'st Jan 2025
OKYO Pharma Ltd (NASDAQ:OKYO) is uniquely positioned to emerge as a key player in the ocular treatment arena as it advances its lead therapeutic candidate OK-101, analysts at Goldman Small Cap Researc
OKYO Pharma insiders acquire shares
09:25am, Friday, 31'st Jan 2025
OKYO Pharma Ltd (NASDAQ:OKYO) announced that its chief executive officer Gary Jacob has purchased 10,000 of the company's shares at US$1.04 per share. Additionally, Panetta Partners, in which executi
OKYO Pharma Announces Chairman and CEO Acquire Shares
07:00am, Friday, 31'st Jan 2025
LONDON and NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic c
Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited
09:45am, Thursday, 30'th Jan 2025
BALTIMORE, MD / ACCESS Newswire / January 30, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published
OKYO Pharma nears full enrollment for neuropathic corneal pain trial with results expected by year-end
10:10am, Wednesday, 29'th Jan 2025
OKYO Pharma Ltd (NASDAQ:OKYO) has provided an update on its clinical programs along with the release of interim financial results for the six months ending in September 2024. The company said it expe
OKYO Pharma secures non-dilutive funding to advance clinical programs
08:46am, Wednesday, 22'nd Jan 2025
OKYO Pharma Ltd (NASDAQ:OKYO) has announced the receipt of $1.4 million in non-dilutive funding. The clinical-stage biopharmaceutical company is developing novel therapies for neuropathic corneal pain
MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
09:00am, Friday, 15'th Nov 2024
ORLANDO, FL / ACCESSWIRE / November 15, 2024 / RedChip Companies will air interviews with MUSQ Global Music Industry ETF (NYSE:MUSQ) and OKYO Pharma Ltd. (Nasdaq:OKYO) on the RedChip Small Stocks, Big
